Companies / Metagenomi Therapeutics, Inc.

Metagenomi Therapeutics, Inc.

Nasdaq: MGXCIK 1785279EMERYVILLE, CA

Financials · FY2025

Revenue$25.21M
Net income$-87.87M
Total debt
Cash$39.03M
Diluted EPS$-2.36
Shares outstanding37.8M

Ownership

37.8M shares outstanding · as of Aug 6, 2026
1.7%Insiders
Ownership
Insiders1.68%635,694
Institutions19.06%7,200,256
Public float79.26%29,941,155

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 5

View all →
Insider% of sharesShares
Irish JianCEOChief Executive Officer · Director
0.88%333,770
Wapnick PamelaChief Financial Officer
0.50%187,375
Wein MatthewSee Remarks
0.30%114,549

Institutional holders 57

View all →

Activity

InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Mar 5, 2026Irish Jian
CEO
SellCommon Stock$2.6K-2K
-0.48%
333,770
0.88% of shares
low
Mar 5, 2026Wapnick Pamela
Executive
SellCommon Stock$2.5K-2K
-0.84%
187,375
0.50% of shares
low
Mar 5, 2026Wein Matthew
Executive
SellCommon Stock$771-482
-0.42%
114,549
0.30% of shares
low
Dec 5, 2025Irish Jian
CEO
GiftCommon Stock$0-228K
-40.52%
335,377
0.89% of shares
low
Jun 9, 2026Dere Willard H
Director
GrantStock Option (Right to Buy)+21K
21,000
0.06% of shares
low
Jun 9, 2026Bjerkholt Eric
Director
GrantStock Option (Right to Buy)+21K
21,000
0.06% of shares
low

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
MGXCommon StockEquity59102M104BBG00Y5ZXS77